Market Access is crucial for the pharmaceutical industry's success, especially as healthcare systems worldwide face increasing cost constraints and payers gain influence over access decisions. To succeed, companies must understand the needs of key stakeholders, including patients, healthcare professionals, providers, payers, and policymakers, and how they interact and assess value. This requires knowledge of stakeholders' decision-making frameworks, goals, priorities, and strategies. This course offers a foundational understanding of Market Access regulations, with a focus on both global perspectives and the German archetype. It covers core principles of pricing, negotiations, Evidence-Based Medicine, Health Technology Assessment, Clinical Trials Methodology, and Health Economics. The course aims to (1) provide a basic understanding of Market Access regulations, stakeholders, processes, and methodologies; (2) equip you with a toolbox for selecting appropriate Market Access strategies; and (3) offer insights from experts to enhance your confidence in managing Market Access projects and strategic discussions.
- Critically assess Market Access strategies
- Define the critical path of activities to achieve and maintain broad Market Access at an optimal price
- Support Market Access projects
This course is part of the prestigious part-time Pharma MBA program, conducted in English on Fridays and Saturdays on Campus Westend. It offers a valuable opportunity to network and gain expertise without committing to a full degree program. As the number of seats is limited, we recommend to register early. If you're a GBS or Goethe University alumni, explore our attractive alumni discount options.
Duration
Location
Language
Course fee
Participants have the choice of completing the course with a qualified certificate or attending as a guest auditor. As an auditor, you are not required to complete assignments, take exams or earn academic credits.
| ECTS | Certificate | |
|---|---|---|
| Guest auditor | - | Certificate of Participation |
| Full participant | 5 CP | Qualified Certificate |
Dr. Ingolf Griebsch
Dr. Ingolf Griebsch is Vice President & Head of Corporate Market Access Oncology at Boehringer Ingelheim. With a PhD in Health Economics from the University of Bristol, he has over 25 years of experience in outcomes research, health technology assessments, and market access in both academia and industry. He currently leads the international SISAQOL IMI consortium, focused on recommendations for analyzing patient-reported outcomes in cancer clinical trials.
Dr. Stephan Linden
Dr. Stephan Linden (PharmD, PhD) is a Health Economics & Outcomes Research Lead at Boehringer Ingelheim. He has more than 15 years of global experience in academia and industry. Stephan lives daily his passion to maximize Patient Access to high-Value Care with real-world evidence and Health Economics.
Dr. Andreas Henschel
Dr. Andreas Henschel is the Head of Health Technology Assessment in Germany at Boehringer Ingelheim. He started in the field of Market Access and Health Technology Assessment at Boehringer Ingelheim when the AMNOG was introduced in 2011. As a research associate, Andreas focused on the methods of evidence-based medicine, clinical uncertainty, and ethical implications.
Dr. Matthias Pfannkuche
Dr. Matthias Pfannkuche, Vice President & Head of Global Market Access & Pricing Operations at Merck KGaA Darmstadt, has nearly 15 years of experience in Market Access, Pricing & Contracting, Health Technology Assessment, and Government Affairs. He has gained extensive expertise through global, regional, and local roles at Merck and Boehringer Ingelheim. As a Postgraduate & Research Associate, he collaborated with leading health insurance companies and government bodies to optimize drug management quality and efficiency.
Dr. Markus König
Dr. Markus König is the Negotiation Lead at Abbvie Deutschland and a seasoned expert in pricing and price negotiations between payers and pharmaceutical companies in Germany under the AMNOG legislation. Markus has conducted numerous price negotiations for both the National Association of Statutory Health Insurance Funds (GKV-SV) and the pharmaceutical industry. He holds a PhD in engineering and is a trained chemical engineer.
Justine Rochon
Justine Rochon is Senior Vice President & Global Head of Biostatistics and Data Sciences at Boehringer Ingelheim. With over 20 years of experience in both academia and the pharmaceutical industry, she combines expertise in Biostatistics and Psychology with visionary leadership. Justine also serves as president of the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and lectures in Biostatistics at the University of Heidelberg, Germany.
| Date | Session |
|---|---|
| Dates coming soon | This course is fully boooked |